Class information for:
Level 1: RADIOIMMUNOTHERAPY//PRETARGETING//Y 90 IBRITUMOMAB TIUXETAN

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
4884 1638 38.6 78%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
701 12232 RADIOIMMUNOTHERAPY//BISPECIFIC ANTIBODIES//EP CAM

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 RADIOIMMUNOTHERAPY Author keyword 273 42% 31% 506
2 PRETARGETING Author keyword 85 65% 5% 82
3 Y 90 IBRITUMOMAB TIUXETAN Author keyword 40 71% 2% 32
4 I 131 TOSITUMOMAB Author keyword 32 88% 1% 15
5 IBRITUMOMAB TIUXETAN Author keyword 30 60% 2% 32
6 PATIENT SPECIFIC DOSIMETRY Author keyword 27 78% 1% 18
7 MOL MED IMMUNOL Address 26 42% 3% 48
8 ZEVALIN Author keyword 25 63% 2% 25
9 PRETARGETED RADIOIMMUNOTHERAPY Author keyword 23 79% 1% 15
10 YTTRIUM 90 IBRITUMOMAB TIUXETAN Author keyword 19 70% 1% 16

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 RADIOIMMUNOTHERAPY 273 42% 31% 506 Search RADIOIMMUNOTHERAPY Search RADIOIMMUNOTHERAPY
2 PRETARGETING 85 65% 5% 82 Search PRETARGETING Search PRETARGETING
3 Y 90 IBRITUMOMAB TIUXETAN 40 71% 2% 32 Search Y+90+IBRITUMOMAB+TIUXETAN Search Y+90+IBRITUMOMAB+TIUXETAN
4 I 131 TOSITUMOMAB 32 88% 1% 15 Search I+131+TOSITUMOMAB Search I+131+TOSITUMOMAB
5 IBRITUMOMAB TIUXETAN 30 60% 2% 32 Search IBRITUMOMAB+TIUXETAN Search IBRITUMOMAB+TIUXETAN
6 PATIENT SPECIFIC DOSIMETRY 27 78% 1% 18 Search PATIENT+SPECIFIC+DOSIMETRY Search PATIENT+SPECIFIC+DOSIMETRY
7 ZEVALIN 25 63% 2% 25 Search ZEVALIN Search ZEVALIN
8 PRETARGETED RADIOIMMUNOTHERAPY 23 79% 1% 15 Search PRETARGETED+RADIOIMMUNOTHERAPY Search PRETARGETED+RADIOIMMUNOTHERAPY
9 YTTRIUM 90 IBRITUMOMAB TIUXETAN 19 70% 1% 16 Search YTTRIUM+90+IBRITUMOMAB+TIUXETAN Search YTTRIUM+90+IBRITUMOMAB+TIUXETAN
10 LYM 1 17 75% 1% 12 Search LYM+1 Search LYM+1

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 RADIOIMMUNOTHERAPY 115 24% 26% 422
2 IODINE I 131 TOSITUMOMAB 100 67% 5% 89
3 FRACTIONATED RADIOIMMUNOTHERAPY 90 77% 4% 62
4 REFRACTORY LOW GRADE 83 50% 7% 120
5 IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY 80 50% 7% 117
6 I 131 LYM 1 ANTIBODY 73 88% 2% 35
7 Y 90 IBRITUMOMAB TIUXETAN 67 60% 4% 73
8 IDEC Y2B8 RADIOIMMUNOTHERAPY 67 85% 2% 35
9 I 131 TOSITUMOMAB 60 59% 4% 68
10 I 131 LYM 1 57 95% 1% 19

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 17 11% 9% 148

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy 2006 172 91 73%
Advances in the treatment of hematologic malignancies using immunoconjugates 2014 13 91 42%
Tumor Immunotargeting Using Innovative Radionuclides 2015 1 86 30%
Radioimmunotherapy of Lymphoma: Bexxar and Zevalin 2010 39 15 87%
Pretargeted Molecular Imaging and Radioimmunotherapy 2012 24 107 54%
Clinical radioimmunotherapy-the role of radiobiology 2011 29 150 56%
Radioimmunotherapy of non-Hodgkin lymphomas 2003 107 38 79%
Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report 2011 17 34 79%
Cancer radioimmunotherapy 2011 29 246 45%
Radioimmunotherapy for B-cell lymphoma: Y-90 ibritumomab tiuxetan and I-131 tositumomab 2007 51 78 60%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 MOL MED IMMUNOL 26 42% 2.9% 48
2 SECT RADIODIAG THER Y 15 82% 0.5% 9
3 GARDEN STATE CANC 15 35% 2.1% 35
4 SECT RADIODIAGNOSIS THER Y 6 100% 0.2% 4
5 HLTH PHYS POST 4 75% 0.2% 3
6 MOL PHARMACOL THER Y SERV 4 75% 0.2% 3
7 RADIAT ONCOL RADIAT 3 50% 0.3% 5
8 UNIT 463 3 50% 0.3% 5
9 RADIODIAG THER Y 3 57% 0.2% 4
10 ELECT SCI PLICAT PHYS 3 100% 0.2% 3

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000228733 ANTIBODY IMMUNOCONJUGATES AND RADIOPHARMACEUTICALS//RADIOIMMUNOGUIDED SURGERY//IMMUNOSCINTIGRAPHY
2 0.0000204886 AT 211//TARGETED ALPHA THERAPY//BI 213
3 0.0000173571 EGF DEXTRAN//ANTIBODY BINDING PARAMETERS//BIOMED RADIAT SCI
4 0.0000167957 GIRENTUXIMAB//G250//MONOCLONAL ANTIBODY CG250
5 0.0000149964 AUGER ELECTRONS//AUGER ELECTRON EMITTER//CELLULAR DOSIMETRY
6 0.0000132640 CD20//OFATUMUMAB//OBINUTUZUMAB
7 0.0000098405 HUMAN MONITORING//RADIAT SURVEILLANCE HLTH ASSESSMENT//INTERNAL RADIAT ASSESSMENT SECT
8 0.0000081141 SOMATOSTATIN RECEPTOR SCINTIGRAPHY//PEPTIDE RECEPTOR RADIONUCLIDE THERAPY//OCTREOTATE
9 0.0000080565 FOLLICULAR LYMPHOMA//NON HODGKINS LYMPHOMA//AGGRESSIVE NON HODGKINS LYMPHOMA
10 0.0000073677 RADIOEMBOLIZATION//Y 90 MICROSPHERES//SELECTIVE INTERNAL RADIATION THERAPY